Intranasal (IN) COVID-19 vaccines - a breakthrough

• Autorzy: Gambhir R.S. , Kaur K. , Matariya R. , Singh B. , Sood R. , Singh J.
• Języki publikacji: EN

Abstrakty

EN

Emerging variants of COVID-19 have threatened the effectiveness of intramuscular (IM) vaccines since that are made to target only the spike protein. Development of Intranasal (IN) vaccination has been proven to provide both the mucosal and systemic immune responses for broader and long lasting protection. Many IN vaccine candidates (virus-vectored vaccines, recombinant subunit vaccines and live attenuated vaccines) are in different phases of clinical trials and in near future many companies would be releasing their vaccines into the drug market. Potential advantages of IN vaccination over IM vaccination makes them ideal to be administered in children and developing populations of the world. This paper focuses on the very recent developments in intranasal vaccination with a spotlight on their safety and efficacy concerns. IN vaccination can prove to be game-changer in handling COVID-19 and potential viral contagious diseases in future.

• Wydawca: -
• Czasopismo: Roczniki Państwowego Zakładu Higieny
• Rocznik: 2023
• Tom: 74
• Numer: 1
• Opis fizyczny: p.15-18,fig.,ref.

Twórcy

autor

Gambhir R.S.

• Department of Public Health Dentistry, Rayat and Bahra Dental College and Hospital, Mohali, Punjab, India

autor

Kaur K.

• Fowlerville Dental Center, Fowlerville, MI, United States

autor

Matariya R.

• Department of Oral and Maxillofacial Surgery, Karnavati School of Dentistry, Karnavati University, Gandhinagar, Gujarat, India

autor

Singh B.

• Department of Oral Medicine and Radiology, SGRD Institute of Dental Sciences and Research, Amritsar, Punjab, India

autor

Sood R.

• Department of Periodontology and Implantology, Rayat and Bahra Dental College and Hospital, Mohali, India

autor

Singh J.

• Department of Public Health Dentistry, Rayat and Bahra Dental College and Hospital, Mohali, India

Bibliografia

• 1. Alu A., Chen L., Lei H., Wei Y., Tian X., Wei X.: Intranasal COVID-19 vaccines: From bench to bed. EBioMedicine. 2022;76:103841. doi: 10.1016/j.ebiom.2022.103841.
• 2. Bharat Biotech’s internasal Covid vaccine iNCOVACC gets CDSCO approval under restricted use. Available at: https://www.bharatbiotech.com Accessed on: 17th February, 2023.
• 3. Chavda V.P., Vora L.K., Pandya A.K., Patravale V.B.: Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov Today. 2021;26:2619-36.
• 4. Chandel A., Goyal A.K., Ghosh G., Rath G.: Recent advances in aerosolised drug delivery. Biomed Pharmacother. 2019;112:108601. doi: 10.1016/j.biopha.2019.108601.
• 5. Choudhary O.P., Priyanka., Mohammed T.A., Singh I.: Intranasal COVID-19 vaccines: Is it a boon or bane? Int J Surg. 2021;94:106119. doi: 10.1016/j.ijsu.2021.106119.
• 6. Dhama K., Dhawan M., Tiwari R., Emran T.B., Mitra S., Rabaan A.A., Alhumaid S., Alawi Z.A., Al Mutair A.: COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother. 2022;18:2045853. doi: 10.1080/ 21645515.
• 7. Global COVID-19 cases and deaths continue to decline. Available at: www.cidrap.umn.edu. Accessed on: 8th February, 2023.
• 8. Hebel C., Thomsen A.R.: A survey of mechanisms underlying current and potential COVID-19 vaccines. APMIS. 2023;131:37-60.
• 9. iNCOVACC-Intranasal Vaccine for COVID-19. Available at: www.bharatbiotech.com. Accessed on: 17th February, 2023.
• 10. Kyd J.: Immunity against mucosal pathogens. Hum Vaccin. 2010;6:10016.
• 11. Saffran M., Kumar G.S., Savariar C., Burnham J.C., Williams F., Neckers D.C.: A new approach to the oral administration of insulin and other peptide drugs. Science. 1986;233:1081–4.
• 12. Schwartz R.A., Kapila R.: Pandemics throughout the centuries. Clin Dermatol. 2021;39:5-8.
• 13. Tiboni M., Casettari L., Illum L.: Nasal vaccination against SARS-CoV-2: synergistic or alternative to intramuscular vaccines? Int J Pharm. 2021;603:120686. doi:10.1016 /j.ijpharm.2021.120686.
• 14. Topol E.J., Iwasaki A.: Operation Nasal Vaccine-Lightning speed to counter COVID-19. Sci Immunol. 2022;7:eadd9947.
• 15. Uddbäck I., Cartwright E.K., Schøller A.S., Wein A.N., Hayward S.L., Lobby J., Takamura S., Thomsen A.R., Kohlmeier J.E., Christensen J.P.: Long-term maintenance of lung resident memory T cells is mediated by persistent antigen. Mucosal Immunol. 2021;14:92–9.
• 16. van der Ley P.A., Zariri A., van Riet E., Oosterhoff D., Kruiswijk C.P.: An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. Front Immunol. 2021;12:781280. doi: 10.3389/fimmu.2021.781280.
• 17. Xu H., Cai L., Hufnagel S., Cui Z.: Intranasal vaccine: Factors to consider in research and development. Int J Pharm. 2021;609:121180. doi: 10.1016/j.ijpharm.2021.121180.

Identyfikatory

DOI

10.32394/rpzh.2023.0251